{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T03:06:28Z","timestamp":1648955188894},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.amjcard.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:46:16Z","timestamp":1517406376000},"page":"975-980","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Meta-Analysis Comparing Neurohumoral Antagonist Use in Patients \u226575 Years Versus &lt;75 Years Receiving Cardiac Resynchronization Therapy"],"prefix":"10.1016","volume":"121","author":[{"given":"Ahmed","family":"AlTurki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Alturki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Dorian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff S.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Greiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Kus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidal","family":"Essebag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thao","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2018.01.011_bib0010","first-page":"329","article-title":"Management of chronic heart failure in the older population","volume":"11","author":"Azad","year":"2014","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0015","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/eurheartj\/eht290","article-title":"An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure","volume":"34","author":"Cleland","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0020","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.cardfail.2016.09.023","article-title":"Mode of death in octogenarians treated with cardiac resynchronization therapy","volume":"22","author":"Martens","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0025","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/europace\/eum143","article-title":"Efficacy of cardiac resynchronization therapy in very old patients: the Insync\/Insync ICD Italian Registry","volume":"9","author":"Achilli","year":"2007","journal-title":"Europace"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0030","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0035","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0045","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/europace\/eus376","article-title":"Cardiac resynchronization therapy improves ejection fraction and cardiac remodelling regardless of patients' age","volume":"15","author":"Brambatti","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0050","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/europace\/eun263","article-title":"Long-term effects of cardiac resynchronization therapy in octogenarians: a comparative study with a younger population","volume":"10","author":"Foley","year":"2008","journal-title":"Europace"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0055","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCOUTCOMES.113.000821","article-title":"Left ventricular reverse remodeling, device-related adverse events, and long-term outcome after cardiac resynchronization therapy in the elderly","volume":"7","author":"Hoke","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0060","first-page":"180","article-title":"Intermediate-term mortality and incidence of ICD therapy in octogenarians after cardiac resynchronization therapy","volume":"11","author":"Kelli","year":"2014","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0065","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/pace.12048","article-title":"Outcomes of cardiac resynchronization therapy in the elderly","volume":"36","author":"Killu","year":"2013","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0070","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1540-8167.2011.02011.x","article-title":"Improved outcome with preventive cardiac resynchronization therapy in the elderly: a MADIT-CRT substudy","volume":"22","author":"Penn","year":"2011","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/eurjhf\/hfs151","article-title":"Response to cardiac resynchronization therapy in elderly patients (>70 years) and octogenarians","volume":"15","author":"Verbrugge","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0080","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/europace\/euv222","article-title":"Clinical outcomes in cardiac resynchronization therapy-defibrillator recipients 80 years of age and older","volume":"18","author":"Adelstein","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0085","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/ejhf.162","article-title":"Age, prognostic impact of QRS prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14,713 patients in the Swedish Heart Failure Registry","volume":"16","author":"Lund","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0090","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/eurheartj\/eht514","article-title":"Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy","volume":"35","author":"Schmidt","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0095","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/S0140-6736(02)11601-1","article-title":"Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey","volume":"360","author":"Cleland","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ahj.2004.06.030","article-title":"A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications","volume":"149","author":"Ahmed","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0105","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1046\/j.1532-5415.2002.50457.x","article-title":"Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications","volume":"50","author":"Ahmed","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0110","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1093\/eurheartj\/ehn476","article-title":"Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure\u2014Assessment of Reduction in Mortality and Morbidity Programme","volume":"29","author":"Cohen-Solal","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0115","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/gerona\/59.7.M716","article-title":"Use of angiotensin-converting enzyme inhibitors in elderly people with heart failure: prevalence and outcomes","volume":"59","author":"Pedone","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0120","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.158.18.2024","article-title":"Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors","volume":"158","author":"Havranek","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0125","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ehjcvp\/pvv016","article-title":"Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival","volume":"1","author":"Witt","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0140","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0145","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.ejim.2013.08.050","article-title":"Safety and tolerability of spironolactone in elderly patients with heart failure","volume":"24","author":"Vierma","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.amjcard.2018.01.011_bib0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918301188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918301188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T10:28:34Z","timestamp":1535106514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914918301188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0002914918301188"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.01.011","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis Comparing Neurohumoral Antagonist Use in Patients \u226575 Years Versus <75 Years Receiving Cardiac Resynchronization Therapy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}